Beyond Rebates: PhRMA Wants HHS To ‘De-Link’ Supply Chain Compensation From List Price
Executive Summary
Focus should not be limited to rebates in Medicare Part D, manufacturers advise in comments on HHS drug pricing blueprint. Pharmacy benefit managers raise anti-trust issues with shift to upfront discounts.
You may also be interested in...
FTC Competition Hearings: PhRMA, Former Rep. Waxman Advocate Focus On PBMs
FTC is assessing possible changes to competition and consumer protection enforcement law and policy, with a hearing on Innovation and IP Policy set for Oct. 23-24.
HHS Advancing Attack On Rebates With Proposal To Revoke Safe Harbor
Upcoming proposed rule could also provide new anti-kickback safe harbor to facilitate value-based contracts, as manufacturers and payers have urged.
PhRMA Drug Pricing Comments Mainly Stick To Script
With only one new proposal, brand industry association seems to banking on strength of past policy positions as Trump's drug pricing blueprint moves towards implementation stage.